# Male Hypogonadism

Diagnose male hypogonadism only when compatible clinical features coexist with repeatedly low early-morning testosterone, then use gonadotropins to separate testicular failure from central disease, protect fertility, identify reversible causes, and select monitored testosterone replacement when indicated.

**Clinical question:** How should physicians confirm, phenotype, evaluate, and treat male hypogonadism while preserving fertility and identifying central disease?

Updated: 2026-09-16T00:27:52.743834+00:00

## What matters in practice
- Require symptoms or signs plus unequivocally and consistently low testosterone; obtain at least two early-morning total testosterone measurements before diagnosing hypogonadism. [7][11][20]
- Measure LH and FSH after biochemical confirmation: elevated gonadotropins indicate primary testicular failure, whereas low or inappropriately normal values indicate hypothalamic-pituitary disease. [5][11][20]
- Do not begin exogenous testosterone in a man pursuing fertility because testosterone suppresses spermatogenesis; persistent central hypogonadism with fertility goals requires gonadotropin treatment. [5][12]
- During testosterone treatment, obtain urologic evaluation for confirmed PSA increase greater than 1.4 ng/mL from baseline within 12 months, PSA greater than 4.0 ng/mL, or an abnormal digital rectal examination. [20]
- FDA-approved testosterone is for men with low testosterone associated with a medical condition, not age-related testosterone decline alone; recent FDA review found no increased major cardiovascular outcome risk in TRAVERSE, while labeling changes also address blood-pressure effects. [3]

## Confirm deficiency before labeling or treating

Test only when the result will explain compatible clinical findings or change management.

Diagnose male hypogonadism only when symptoms or signs consistent with androgen deficiency coexist with unequivocally and consistently low serum total testosterone and/or free testosterone when indicated. Do not screen the general male population routinely. [20][21]

Obtain total testosterone on at least two separate early-morning samples, preferably before 10 AM; one commonly used biochemical threshold is total testosterone below 300 ng/dL, but interpret results against the reporting laboratory reference interval. A fasting early-morning total testosterone below 300 ng/dL on two occasions in a symptomatic man supports the diagnosis in most cases. [7][11]

Order free testosterone when altered sex hormone-binding globulin may make total testosterone misleading: total testosterone may be low with reduced SHBG in obesity or diabetes and may be elevated with increased SHBG during aging. A discordant total testosterone result should therefore prompt free-testosterone assessment rather than empiric replacement. [11]
- Do not diagnose biochemical hypogonadism from a single low value. Repeat an early-morning measurement before treatment. [7][11][21]
- If testosterone is repeatedly low but the phenotype is nonspecific, identify comorbid or medication-related contributors before assigning a lifelong replacement indication. FDA approval is limited to men with deficient testosterone associated with a medical condition. [3]
- In delayed puberty or absent/incomplete sexual development, prioritize congenital and childhood-onset etiologies rather than applying an adult late-onset framework. [6][14]

*Laboratory confirmation and etiologic interpretation of low testosterone. [5][7][11][20]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Symptoms/signs plus two early-morning total testosterone values below 300 ng/dL or below laboratory range [7][11] | Biochemical hypogonadism is supported [7][20] | Measure LH and FSH to localize the defect. [20] |
| Low total testosterone with obesity or diabetes, or unexpectedly normal/high total testosterone in aging [11] | SHBG variation can distort total-testosterone interpretation [11] | Obtain free testosterone when indicated before treatment decisions. [11][20] |
| Low testosterone with high LH and FSH [5] | Primary testicular failure [5][20] | Review congenital, testicular, toxic, treatment-related, and acquired gonadal causes. [5] |
| Low testosterone with low or normal LH and FSH [5] | Secondary, hypogonadotropic hypogonadism [5][20] | Evaluate hypothalamic-pituitary disease and measure prolactin when a pituitary lesion is a concern. [11] |

## Use LH and FSH to direct the next workup

Gonadotropin pattern determines whether to evaluate the testes or hypothalamic-pituitary axis.

After confirming low testosterone, measure LH and FSH to distinguish primary from secondary hypogonadism. Elevated gonadotropins with low testosterone reflect impaired testicular testosterone production; low or normal gonadotropins with low testosterone are inappropriately low and indicate hypothalamic-pituitary dysfunction. [5][11][20]

For primary hypogonadism, target the history and examination to testicular failure. FDA labeling identifies cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, and toxic injury from alcohol or heavy metals as causes. Klinefelter syndrome classically presents with tall stature, relatively long legs, small firm testes, gynecomastia, azoospermia, and progressive hypogonadism; confirm suspected cases with karyotype testing. [5][19]

For secondary hypogonadism, ask specifically about pituitary tumor, head trauma, cranial irradiation, and congenital GnRH deficiency. Obtain serum prolactin if a pituitary tumor is a concern; suspected hypogonadotropic hypogonadism or pituitary disease is an indication for pituitary MRI. [5][11][18]

In men with congenital hypogonadotropic hypogonadism, delayed or arrested puberty is the usual presentation. In infancy, cryptorchidism with or without micropenis should trigger consideration of congenital hypogonadotropic hypogonadism, with gonadotropin and sex-steroid profiling at 4 to 8 weeks during mini-puberty. [14]
- Primary pattern: low testosterone plus elevated LH/FSH; investigate testicular injury, prior gonadotoxic therapy, congenital disorders, and Klinefelter syndrome. [5][19]
- Central pattern: low testosterone plus low/normal LH/FSH; assess prolactin and pursue pituitary-directed evaluation when clinical suspicion is present. [11][18]
- In a man with treated prolactinoma and persistent hypogonadism, reassess the gonadal axis at 6-month intervals because recovery may eliminate the replacement indication. [12]

### Prolactinoma-associated hypogonadism

For men receiving prolactinoma therapy who remain hypogonadal for more than 6 months, testosterone replacement can be considered, with caution in large adenomas because of potential adenoma growth. Re-evaluate the testosterone indication every 6 months using prolactin and gonadal-axis results. [12]

Men with persistent hypogonadotropic hypogonadism despite dopamine-agonist treatment and normalized prolactin who desire fertility should receive gonadotropin treatment rather than exogenous testosterone. [12]

*Actionable etiologic branches after low testosterone is confirmed. [5][11][12][14][18][19]*

| Etiologic branch | Discriminating features | Management consequence |
| --- | --- | --- |
| Primary testicular failure [5] | Low testosterone with elevated LH and FSH; history of cryptorchidism, torsion, orchitis, orchiectomy, chemotherapy, or toxic exposure may identify cause. [5] | Treat documented androgen deficiency when appropriate; evaluate reproductive goals and testicular etiology. [5][20] |
| Klinefelter syndrome [19] | Small firm testes, tall stature with relatively long legs, gynecomastia, azoospermia, and progressive hypogonadism. [19] | Confirm with karyotype; infertility may be addressed with testicular sperm extraction and intracytoplasmic sperm injection. [19] |
| Pituitary-hypothalamic disease [5][11] | Low testosterone with low or normal LH/FSH; tumor, trauma, or irradiation history supports central disease. [5] | Measure prolactin when pituitary tumor is suspected and obtain pituitary MRI when hypogonadotropic hypogonadism or pituitary disease is suspected. [11][18] |
| Congenital hypogonadotropic hypogonadism [14] | Delayed or arrested puberty; infant cryptorchidism or micropenis is a clue during mini-puberty. [14] | Exclude pituitary tumor and functional causes; direct fertility treatment toward gonadotropin-based induction when needed. [12][14] |

## Select replacement only after fertility and indication review

Testosterone treatment is replacement therapy, not a substitute for etiologic evaluation.

Offer testosterone therapy to men with confirmed hypogonadism to induce and maintain secondary sexual characteristics and correct manifestations of testosterone deficiency. FDA-approved products are indicated for males with low testosterone associated with primary or hypogonadotropic hypogonadism and are not approved solely for age-related testosterone decline. [2][3][20]

Before prescribing, establish reproductive intent. Exogenous testosterone suppresses spermatogenesis and can produce azoospermia; it is therefore inappropriate for men actively seeking fertility. In persistent central hypogonadism after prolactinoma treatment, use gonadotropin treatment when fertility is desired. [1][5][12]

Choose formulation based on adherence, route preference, exposure risk, and monitoring. Available U.S. testosterone formulations include injections, topical gels and solutions, patches, buccal systems, nasal gel, implantable pellets, and oral products. Topical products can cause local irritation and create transfer risk; nasal formulations require three-times-daily dosing. [1][3]

For testosterone gel 1%, the labeled adult starting dose is 50 mg applied topically once daily. Do not interchange topical products by milligram dose because strengths, application instructions, and systemic exposure differ among products. [2]

For weekly subcutaneous testosterone enanthate, FDA-reviewed dosing is 50 mg, 75 mg, or 100 mg once weekly. Select a formulation only after ensuring that the patient can follow route-specific administration and monitoring requirements. [1]
- Counsel patients using topical testosterone to prevent secondary exposure: application-site contact should be washed with soap and water as soon as possible. [2]
- Do not use testosterone to preserve fertility; suppression of spermatogenesis is an expected pharmacologic consequence. [1][5]
- Use testosterone only after confirming persistent biochemical deficiency and compatible clinical features, not for nonspecific symptoms with an unconfirmed testosterone abnormality. [20][21]

*Formulation-specific decision points supported by U.S. labeling and FDA review. [1][2][3]*

| Option | Source-supported regimen or feature | Selection issue |
| --- | --- | --- |
| Testosterone gel 1% [2] | Starting dose 50 mg topically once daily. [2] | Products are not dose-interchangeable; local irritation and secondary transfer precautions affect selection. [1][2] |
| Subcutaneous testosterone enanthate [1] | 50 mg, 75 mg, or 100 mg subcutaneously once weekly. [1] | Weekly injection is an alternative to daily topical administration. [1] |
| Nasal testosterone [1] | Requires administration three times daily. [1] | Use only when frequent daily dosing is feasible. [1] |
| Other FDA-approved testosterone routes [3] | Oral, transdermal patch, buccal, injection, and topical gel formulations are available. [3] | Match route to adherence, application burden, and route-specific adverse effects. [1][3] |

## Monitor treatment response, erythrocytosis, prostate signals, and formulation harms

Continue therapy only when clinical benefit is accompanied by acceptable safety surveillance.

Adjust testosterone therapy to achieve physiologic serum testosterone concentrations and improve relevant clinical features without inducing erythrocytosis. Testosterone products can increase hematocrit and PSA; monitor these parameters during treatment. [1][7]

During the first 12 months, obtain urologic consultation for a confirmed PSA increase greater than 1.4 ng/mL above baseline, a confirmed PSA greater than 4.0 ng/mL, or a prostatic abnormality on digital rectal examination. After 1 year, follow standard prostate-cancer screening guidance based on age and race. [20]

Assess for treatment-related edema, particularly in men with pre-existing cardiac, renal, or hepatic disease because androgens can promote sodium and water retention and may cause serious edema with or without congestive heart failure. Ask about sleep-apnea worsening in patients with baseline risk factors and evaluate persistent gynecomastia. [1][2]

FDA’s 2025 class-wide review incorporated TRAVERSE findings showing no increase in major adverse cardiovascular outcomes in men using testosterone for hypogonadism. FDA also required class-wide labeling changes based on ambulatory blood-pressure studies; account for blood-pressure risk during treatment surveillance. [3]
- Track hematocrit because erythrocytosis is a dose-limiting treatment complication. [1][7]
- Recheck PSA changes rather than acting on an unconfirmed isolated increase; the referral triggers require confirmed PSA change or level. [20]
- Reassess ongoing need in reversible central etiologies, especially treated prolactinoma, at 6-month intervals. [12]
- Stop framing testosterone as fertility-neutral: azoospermia is a recognized risk of exogenous androgen exposure. [1][5]

*Treatment surveillance triggers that change management. [1][2][3][12][20]*

| Monitoring finding | Clinical implication | Next step |
| --- | --- | --- |
| Confirmed PSA increase >1.4 ng/mL from baseline in first 12 months [20] | Potential prostate abnormality requiring evaluation. [20] | Obtain urologic consultation. [20] |
| Confirmed PSA >4.0 ng/mL or abnormal digital rectal examination [20] | Meets guideline trigger for urologic evaluation. [20] | Obtain urologic consultation. [20] |
| Rising hematocrit during treatment [1][7] | Erythrocytosis is a recognized testosterone adverse effect. [1][7] | Adjust therapy to avoid erythrocytosis while targeting physiologic testosterone concentrations. [7] |
| Edema in cardiac, renal, or hepatic disease [2] | Androgen-associated sodium and water retention can be serious. [2] | Evaluate severity and reassess testosterone treatment. [2] |
| Persistent hypogonadism after prolactinoma treatment [12] | The gonadal axis may recover after prolactin control. [12] | Re-evaluate prolactin, testosterone, and replacement need every 6 months. [12] |

## Common questions

### Should an older man with low testosterone receive testosterone therapy for age-related decline alone?

No. FDA-approved testosterone is limited to men with low testosterone associated with an underlying medical condition; treatment should follow confirmation of compatible clinical features and consistently low testosterone. [3][20]

### When does low testosterone require pituitary evaluation?

Low testosterone with low or inappropriately normal LH and FSH indicates central hypogonadism. Measure prolactin when pituitary tumor is a concern and obtain pituitary MRI for suspected hypogonadotropic hypogonadism or pituitary disease. [5][11][18]

## References
1. [PDF] Risk Assessment adn Risk Mitigation Review(s) - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209863Orig1s000RiskR.pdf
2. [PDF] 202763Orig1s000 | FDA - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202763Orig1s000Lbl.pdf
3. FDA issues class-wide labeling changes for testosterone products | FDA — www.fda.gov — https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
4. [PDF] ANDRODERM - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=e58a5328-fdd9-40cb-a19f-8ed798989b9c
5. These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively. See full prescribing information for TESTOSTERONE GEL, 1%. TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=353de205-d642-4f26-875b-b9ea4707a755&type=display
6. Pediatric Male Hypogonadism — www.fda.gov — https://www.fda.gov/media/123592/download
7. Hypogonadism in men - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/1093?locale=de
8. Supplementary appendix - The Lancet — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S1470-2045(18)30649-1/attachment/df0e306b-1f1b-4bc2-aeb7-7fe44ff8e7b4/mmc1.pdf
9. Reversal of Idiopathic Hypogonadotropic Hypogonadism — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa066494
10. Comment on: Variations in diagnostic criteria for male hypogonadism: is there a need for standardizing specialist society guidelines? | International Journal of Impotence Research — www.nature.com — https://www.nature.com/articles/s41443-025-01164-w
11. Testosterone and Cardiovascular Disease - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2015.12.005
12. Diagnosis and management of prolactin-secreting pituitary adenomas — www.nature.com — https://www.nature.com/articles/s41574-023-00886-5
13. Prediction of Long-term Post-operative Testosterone Replacement Requirement Based on the Pre-operative Tumor Volume and Testosterone Level in Pituitary Macroadenoma | Scientific Reports — www.nature.com — https://www.nature.com/articles/srep16194
14. European Consensus Statement on congenital hypogonadotropic ... — www.nature.com — https://www.nature.com/articles/nrendo.2015.112
15. Testosterone Deficiency: A Review and Comparison of Current Guidelines - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1743609519307192
16. Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S002561961500467X
17. EAU Guidelines on Sexual and Reproductive Health: A Summary of the 2026 Recommendations for Measurement and Biochemical Confirmation of Hypogonadism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2405456926000647
18. Management of Azoospermia: A Systematic Approach - Raza - 2026 — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/tog.70043
19. Klinefelter syndrome: more than hypogonadism — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0026049518300283
20. Testosterone Therapy for Hypogonadism Guideline Resources | Endocrine Society — www.endocrine.org — https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy#1
21. [PDF] Endocrine Society Testimony to the — www.endocrine.org — https://www.endocrine.org/-/media/endocrine/files/advocacy/society-testimony/2014-09-17-fda-testosterone-testimony.pdf
22. Expert Opinion on the Diagnosis and Management of Male Hypogonadism in India - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9977550
23. Testosterone Therapy in Men With Hypogonadism - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/29562364
24. Current National and International Guidelines for the Management ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7520594

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.